Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology™

Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection – (available: https://www.mdpi.com/2076-0817/12/1/77), in the special edition of Pathogens by MDPI, a Swiss based medical journal. The article written by Professor John Alderete from the School […]
MedMira Introduces VYRA TriDemic

Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRA™ product line, the VYRA™ TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV). VYRA™ TriDemic, a four-in-one test, which is a direct response to the […]
MedMira receives CE mark for its VYRA™ COVID-19 Antigen Test

Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), the fastest SARS-CoV-2 Antigen test available. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. MedMira […]
MedMira Receives Grant from John Hopkins for its Multiplex STD Saliva Test

Halifax, Nova Scotia, 26 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) received the confirmation letter from the John Hopkins School of Medicine, Division of Infectious Diseases stating that MedMira’s proposal titled “RVF Technology Multiplex saliva test for Sexually Transmitted Diseases (STDs)” was selected by the panel of experts and awarded a development grant. […]
New development of gold nano-particles

MedMira is continuously developing more ways to expand on future potentials of its RVF Technology, if this is customer satisfaction, increase of output or supporting regulatory for additional claims. In collaboration with researchers, Dr. Xu Zhang and Dr. Andrew Carrier at Cape Brenton University, and with the great support of NSBI (Nova Scotia Business Inc […]
Multiplo® Product Line – A Simple Solution in One

MedMira’s unique Multiplo® Product Line: Did you know, MedMira is working with a number of cruise lines which offer MedMira’s Multiplo® products on their ships for immediate screening of various diseases. The easy-to-use and fast handling is the perfect all-in-one test in ANY setting.
MedMira Receives Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology™ (RVF) based diagnostic tests. This […]
MedMira’s COVID-19 Tests – for ANY STAGE

Download the MedMira COVID-19 testing overview
Product and Regulatory Update on MedMira’s COVID-19 Product Family

Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. MedMira has utilized its patented Rapid Vertical Flow™ (RVF™) technology and developed the company’s first rapid antigen test,VYRA CoV-2 Antigen Test (VYRA CoV-2), designed to detect SARS-CoV-2 […]
MedMira Announces Update on Development of Point-of-Care Antibody Test

Halifax, Nova Scotia, 15th of April, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow™ (RVF) technology, the newly developed REVEALCOVID-19™ delivers immediate results without the need for any additional […]